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A B S T R A C T
Human telomerase reverse transcriptase (hTERT) contributes to tumor progression as well as maintain-
ing telomere length, however, the mechanism by which hTERT promotes invasiveness is not yet completely
understood. This study aims to unravel the precise mechanism through which hTERT promotes cancer
invasion. We established an hTERT-overexpressed immortalized cell line (IHOK/hTERT). In orthotopic xe-
nograft models, IHOK/hTERT harbors higher tumorigenicity than IHOK/Control. IHOK/hTERT showedmuch
higher migration and invasion activities compared to IHOK/Control. IHOK/hTERT co-cultured with ﬁ-
broblasts displayed increased invasion compared to IHOK/hTERT without ﬁbroblasts. We screened for
genes that play an important role in intermodulation between cancer cells and ﬁbroblasts using amicroarray
and identiﬁed ﬁbroblast activation protein (FAP). hTERT knockdown showed decreased expression of FAP
and early growth response (EGR)-1, one of the transcriptional regulators of FAP in IHOK/hTERT and oral
cancer cell line YD10B. Furthermore, EGR-1 knockdown in IHOK/hTERT and YD10B showed reduced in-
vasion and reduced cathepsin D expression compared to Control-siRNA cells. Taken together, this study
provides evidence that hTERT overexpression is responsible for the upregulation of the cysteine prote-
ase cathepsin D by regulating EGR-1 to activate invasiveness in cancer progression.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth
most common malignancy in the world. Oral squamous cell carci-
noma (OSCC) comprises approximately 10% of HNSCC, in general,
but almost one-third in speciﬁc geographic areas [1,2]. Despite the
advances in therapeutic approaches, an overall 5-year survival rate
of OSCC patients has been estimated for the lowest 25% [2].
Infection with human papilloma virus (HPV) is one of the leading
causes of HNSCC, especially cancer in the oropharynx and base of
the tongue. OSCC is the second most common high risk-HPV (hr-
HPV)-related cancer, and its incidence is gradually increasing [2,3].
hr-HPV causes human cancers by expressing two viral oncoproteins,
E6 and E7. The expressions of E6 and E7 alone are not suﬃcient for
cellular transformation, and additional genetic alterations are nec-
essary formalignant progression [4]. E6 and E7 havemultiple binding
partners that exert oncogenic effects beyond the degradation of p53
and pRb. For example, E6, in concert with E6AP, induces telomerase
activity through the activation of human telomerase reverse tran-
scriptase (hTERT) via degradation of NFX1, a transcription repressor
of hTERT, thus contributing to cellular immortalization [5].
The catalytic subunit of telomerase, hTERT, is overexpressed in ap-
proximately 90% of human cancer cells, suggesting that hTERT is
indispensable for cancer progression [6]. In addition tomaintaining the
telomere length for cellular immortalization, hTERT has been shown
to play an active role in tumor progression by inducing mobility, in-
vasion, and anti-apoptosis of cancer cells, supporting independent roles
for telomerase beyond telomere lengthening [7–9]. A recent ﬁndingpro-
vided evidence that hTERT is involved in invasion through the
modulation ofmatrixmetalloproteinase (MMPs) expression [10]. In our
previous study, we also found that knockdown of hTERT reduced in-
vasiveness in both hr-HPV- and non-infected OSCC through down-
regulation of MMP2 and MMP9 expression [11]. MMPs play an
important role in various physiological and pathological processes. In
particular, MMPs are prime candidates for invasion andmetastasis ac-
tivities. Although several MMP inhibitors have been investigated in
clinical trials for various cancers, none of these trials have demon-
strated satisfactory eﬃcacy, likely due to the lack of inhibitor speciﬁcity
and unclear scientiﬁc mechanism [12–14]. Accordingly, it is neces-
sary todiscover an effectivemolecular target and supportingmechanism
as a substitute for MMPs for current anticancer therapy.
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A recent ﬁnding showed that cathepsin, but not MMPs, is sig-
niﬁcantly associated with poor survival [15]. However, there are
fewer studies that connect cathepsins with carcinogenesis com-
pared with MMPs. Cathepsins are lysosomal cysteine proteases that
degrade the extracellular matrix (ECM) and thus play active roles
in the invasion and metastasis of cancer cells. Among the cathep-
sins, cathepsin D is an invasion promoter and plays a critical role
in various cancers including OSCC [16,17]. According to our previ-
ous study [18], cathepsin D expression in cancer cells was increased
by ﬁbroblast stimulation in collagen gel-based co-cultured models,
suggesting that cathepsin D expression is related to cancer inva-
sion via crosstalk between cancer cells and stromal ﬁbroblasts.
Here, this study aims at investigating the role of hTERT in in-
vasion related to crosstalk between cancer cells and stromal
ﬁbroblasts. We demonstrate that hTERT induces invasion by modu-
lating cathepsin D via early growth response (EGR)-1 in HPV-16 E6/
E7-transfected immortalized human oral keratinocytes (IHOK) and
HPV-not related OSCC cells. This new discovery will contribute to
the development of a novel chemotherapeutic approach targeting
hTERT.
Materials and methods
Cell culture
IHOKwas established by transfecting the pLXSN vector containing the E6/E7 open
reading frame of HPV-16 as previously described [19]. IHOK/hTERT and IHOK/
Control were constructed by using plpc-hTERT and pLXRN (Clontech, USA) vectors,
respectively. Each vector was transfected into a GP2-293 packaging cell line to produce
retrovirus particles that were subsequently used to infect IHOK. Four types of OSCC
cells (YD9, YD10B, YD32, and YD38) [20,21] and immortalized human gingival ﬁ-
broblasts (hTERT-hNOF) were used for this study [22]. Details about the cell culture
procedures are described in the Supplementary Materials and Methods.
Co-culture
IHOK/hTERT, YD10B, and siRNA-transfected cells were co-cultured with hTERT-
hNOF to observe whether ﬁbroblasts have an impact on protein expression. The
Supplementary Materials and Methods are described in details.
Mouse orthotopic xenograft model
The animal studies were approved by the animal ethics committee at Yonsei Uni-
versity College of Dentistry. BALB/cmalemice (16 ± 2 g, 4 weeks of age) were provided
from Orient Bio Incorporation (South Korea). Cells (5 × 105) were injected into the
dorsal tongue of 15 mice in each group. Three mice in the IHOK/Control-injected
group died during the procedure. The mice were then sacriﬁced after 6 weeks. The
tongues of the mice were ﬁxed in 10% neutral formalin, embedded in paraﬃn, sec-
tioned, and stained with hematoxylin and eosin for morphologic analysis. The tumor
volume was assessed by two-dimensional measurements [23].
Immunoﬂuorescence observation
Immunoﬂuorescence staining was performed to detect protein expression of
hTERT between IHOK/Control and IHOK/hTERT. The details were described in the
Supplementary Materials and Methods.
BrdU incorporation assay
Cell proliferation was measured by the BrdU Flow Kit (BD Pharmingen™, UK)
according to the manufacturer’s instructions.
Telomerase repeat ampliﬁcation protocol (TRAP) assay
Telomerase activity was measured by the Telomerase TeloTAGGG PCR ELISA
(Roche, Switzerland) according to the manufacturer’s instructions using 0.05 and
0.5 μg total protein.
Wound-healing migration assay
Cells (3 × 105) were seeded on 6-well plates and allowed to adhere overnight
in growth media containing 1% FBS to achieve up to 90% conﬂuence. The mono-
layer was scratched using a sterile 200 μL pipette tip. After 24 h, wound closure was
evaluated by light microscopy (Olympus, Japan).
Invasion assay
Invasion assay was performed to compare the invasive activity between IHOK/
Control and IHOK/hTERT. The Supplementary Materials and Methods are described
in details.
Organotypic culture
Organotypic culturewas performed to conﬁrm the invasive activity between IHOK/
Control and IHOK/hTERT. The Supplementary Materials and Methods are described
in details.
Polymerase chain reaction (PCR)
Total DNA was extracted from each cell line using QIAamp DNAminikit (Qiagen,
Germany). The primer sequences are listed in Table S1. DNA was ampliﬁed by using
Accu Power Hot Start PCR Pre Mix (Bioneer, South Korea) with the following con-
ditions: 30 cycles of 30 s at 94 °C, 30 s at 60 °C, and 40 s at 72 °C. The ampliﬁed
products were separated on 1.0% agarose gel stained with 0.1 μg/mL of ethidium
bromide, and photographed under UV light (Bio-Rad, USA).
Reverse transcription–polymerase chain reaction (RT–PCR)
Total RNA was extracted from each cell line using a RNeasy plus mini kit (Qiagen,
Germany), and complementary DNA was synthesized using the 2.5× RT-&GO™
Mastermix (MP Biomedicals, USA) according to the manufacturer’s instructions. The
primer sequences are listed in Table S1. Details about the procedures of RT−PCR are
described in the Supplementary Materials and Methods.
siRNA transfection
Cells (1.5 × 105) were seeded in a 6-well plate for 24 h before transfection. hTERT-
speciﬁc siRNA, EGR-1-speciﬁc siRNA, and control siRNA were the products of Bioneer
Corporation (South Korea). Transfection of siRNAwas performed using Lipofectamine
RNAi MAX (Invitrogen, USA) according to the manufacturer’s instruction. Total RNA
and proteins were extracted 48 h after transfection. The sequences of siRNA are listed
in Table S2.
Western blotting and zymography
Cells were lysed using a lysis buffer (Cell Signaling, USA) and used for western
blotting. Collected conditionedmediumwas used for zymography. Details about pro-
cedures are described in the Supplementary Material and Methods.
Microarray data analysis
Microarray was performed to ﬁnd altered gene expressions between IHOK/
Control and IHOK/hTERT. The Supplementary Materials and Methods are described
in details.
Statistical analysis
Statistical analysis was performed using the Mann–Whitney U test to deter-
mine the statistical signiﬁcance. All of the variables were tested in three independent
experiments, and each experiment was performed at least in triplicate. The results
are reported as the mean ± standard deviation (SD). The value of p < 0.05 was con-
sidered statistically signiﬁcant.
Results
Construction of the hTERT-overexpressed cell line
To evaluate the functional signiﬁcance and mechanism of hTERT
on cancer invasion, we established hTERT-overexpressed immor-
talized cells (IHOK/hTERT). No signiﬁcant change inmorphology was
observed between IHOK/Control and IHOK/hTERT (Fig. S1A). HPV-
16 E6 and E7 DNA infection was conﬁrmed in IHOK/Control and
IHOK/hTERT by PCR (Fig. 1A). The mRNA expression levels of hTERT
exhibited much higher in IHOK/hTERT than IHOK/Control, conﬁrm-
ing exogenous hTERT was successfully expressed in IHOK/hTERT
(Fig. 1B). The expression of hTERT was also conﬁrmed by immu-
noﬂuorescence staining (Fig. 1C and D). Signiﬁcant difference in
telomerase activity was observed between IHOK/Control and IHOK/
hTERT when TRAP assay was performed using 0.05 μg total protein
(Fig. 1E). No signiﬁcant difference in proliferative activity was ob-
served between the two cell lines when a BrdU incorporation assay
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was performed (Fig. 1F). We conﬁrmed that IHOK/Control and
IHOK/hTERT were derived from IHOK by autosomal short tandem
repeats (STR) proﬁling (Table S3).
Comparison of in vivo tumorigenesis between IHOK/Control and
IHOK/hTERT
To investigate the effect of hTERT on in vivo tumorigenesis, IHOK/
Control and IHOK/hTERT were injected into the dorsal tongues of
nude mice. After 6 weeks, 3 out of 12 mice (25%) in the IHOK/
Control-injected group showed tumor formation, while 12 out of
15 mice (80%) formed tumors in the IHOK/hTERT-injected group
(Fig. 2A and B). The tumor volume in IHOK/hTERT-injectedmice was
signiﬁcantly higher than in IHOK/Control-injected mice (Fig. 2C).
These results indicate that IHOK/hTERT harbors higher tumorige-
nicity than IHOK/Control.
Difference of migration and invasion activities between IHOK/Control
and IHOK/hTERT
To investigate whether hTERT induces migration and invasion
to enhance tumorigenicity, we examined the effect of hTERT on cell
migration by a wound healing assay. IHOK/hTERT displayed a
2.5-fold increase in migratory activity compared to IHOK/Control
(Fig. 3A and B). To determine whether hTERT is involved in the in-
duction of cell invasion, we performed an invasion assay in the
presence and absence of ﬁbroblasts in the lower layer. IHOK/hTERT
showed a 2-fold increase in invasive activity compared to IHOK/
Control in the absence of ﬁbroblasts in the lower well (Fig. 3C and
D).When epithelial cells were stimulated by ﬁbroblasts, IHOK/hTERT
showed a 4-fold increase in invasiveness compared to IHOK/
Control (Fig. 3C and D). IHOK/hTERT co-cultured with ﬁbroblasts
showed higher invasive activity than IHOK/hTERT cultured without
ﬁbroblasts (Fig. 3D). In addition, we conﬁrmed the invasive activ-
ity of IHOK/hTERT using an organotypic culture. IHOK/hTERT
displayed a 1.8-fold increase in invasive activity compared to IHOK/
Control (Fig. 3E and F). Taken together, IHOK/hTERT showed higher
invasiveness than IHOK/Control. The co-cultured condition with ﬁ-
broblasts facilitated the invasiveness of IHOK/hTERT.
Overexpressed genes in IHOK/hTERT compared to IHOK/Control
We performed a large-scale genomic screening three times to
identify altered gene expression patterns between IHOK/Control and
Fig. 1. Construction of the hTERT-overexpressed cell line. (A) HPV-16 E6 and E7 DNA expressions in IHOK/Control and IHOK/hTERT. (B) The mRNA expression of hTERT in
IHOK/Control and IHOK/hTERT was measured by RT–PCR. GAPDH was used as a loading control. (C) Immunoﬂuorescence examination of hTERT expression in IHOK/Control
(upper) and IHOK/hTERT (lower). hTERT (green), nucleus (DAPI; blue) (magniﬁcation: 200×, Scale bar: 50 μm). (D) Fluorescence intensity of hTERT in IHOK/Control and
IHOK/hTERT. hTERT expression was normalized to each DAPI intensity. The results are shown as the mean value ± SD (n = 3) and were analyzed by the Mann–Whitney U
test (**p < 0.01). (E) Telomerase activity of IHOK/Control and IHOK/hTERT. Telomerase activity was measured by the TRAP assay using 0.05 and 0.5 μg total protein. Hela is
a positive control of telomerase activity. The results are shown as the mean value ± SD (n = 3) and were analyzed by the Mann–Whitney U test. (F) BrdU assay of IHOK/
Control and IHOK/hTERT. The results are shown as the mean value ± SD (n = 3) and were analyzed by the Mann–Whitney U test. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
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IHOK/hTERT. We ﬁrst screened invasion-related genes because the
invasion activity of IHOK/hTERT was higher than that of IHOK/
Control. MMP2 andMMP9 showed a 1.36-fold and 1.79-fold increase
in IHOK/hTERT compared with IHOK/Control, respectively (Table 1).
Although these microarray data were not conﬁrmed at the mRNA
levels, gelatin zymography showed higher MMP2 and MMP9 ac-
tivities in IHOK/hTERT than in IHOK/Control (Fig. S1). Based on the
observation that the difference in invasion activity between the two
cell lines was much higher when co-cultured with ﬁbroblast com-
pared tomono-cultured conditions, we analyzed the genomic screen
to identify the genes that are associated with functions modulat-
ing ﬁbroblasts. Fibroblast growth factor 2 (FGF2), FGF11, ﬁbroblast
growth factor receptor 3 (FGFR3), and ﬁbroblast activation protein
(FAP) were up-regulated in IHOK/hTERT compared with IHOK/
Control (Table 2). To conﬁrm the microarray data, mRNA expression
of FAP, FGF2, FGF11, and FGFR3 was measured in the two cell lines.
Among them, FAP showed the highest expression level in
IHOK/hTERT compared to IHOK/Control (Fig. 4A and B).
FAP and EGR-1 expression regulated by hTERT
To evaluate whether hTERT regulates FAP expression, we used
siRNA to knock down the expression of hTERT in IHOK/hTERT. Ex-
pression of hTERT mRNA was reduced up to 59% in IHOK/hTERT
transfected with hTERT-siRNA (Fig. 4C and D). Increased FAP ex-
pressionwith hTERT overexpressionwas reduced up to 50% following
hTERT knockdown, conﬁrming that hTERT regulates FAP (Fig. 4C–E).
To investigate the mechanism underlying hTERT-mediated regula-
tion of FAP, the levels of transcription factors that modulate FAP
expression were screened [24]. Only the mRNA and protein
Fig. 2. Comparison of in vivo tumorigenesis between IHOK/Control and IHOK/hTERT. (A) Representative pictures of tumor masses from IHOK/Control-injected mice (upper)
and IHOK/hTERT-injected mice (lower). (B) Representative microscopic pictures of IHOK/Control and IHOK/hTERT in vivo tumorigenicity. Cells (5 × 105) were injected into
dorsal tongues for each cell line. After 6 weeks, the mice were sacriﬁced (magniﬁcation: 40×, scale bar: 200 μm). (C) Tumor volume of IHOK/Control-injected mice and IHOK/
hTERT-injected mice. Tumor volume was assessed by two-dimensional measurements. The results are shown as the mean value ± SD (n = 15) and were analyzed by the
Mann–Whitney U test (*p < 0.05).
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expression of EGR-1 were signiﬁcantly down-regulated by trans-
fection of IHOK/hTERT with hTERT-siRNA (Fig. 4C, D, and F). No
signiﬁcant difference in mRNA expression of speciﬁcity protein 1
(Sp1), E2F transcription factor 1 (E2F1), and homeobox A4 (HOXA4)
was observed between control cells and hTERT-siRNA transfected
cells (Fig. S2). In addition, we veriﬁed that FAP was regulated via
EGR-1 (Fig. S4A, B, E, and F). To conﬁrm the results obtained in IHOK/
hTERT, we screenedmRNA and the protein expression of hTERT, FAP,
Fig. 3. Difference of migratory and invasive activities between IHOK/Control and IHOK/hTERT. (A) The wound-healing migration assay of IHOK/Control and IHOK/hTERT
(magniﬁcation: 40×, scale bar: 200 μm). The conﬂuent monolayer was scratched. After 24 h, wound closure was evaluated. (B) The number of migrated cells was normal-
ized by dividing by the number of total cells to rule out the effect of cell proliferation and presented as the % of migration. The results are shown as the mean value ± SD
(n = 3) and were analyzed by the Mann–Whitney U test (*p < 0.05). (C) The invasion assay of IHOK/Control and IHOK/hTERT in the absence (w/o ﬁbroblasts) or presence
(w/ﬁbroblasts) of ﬁbroblasts in the lower layer (magniﬁcation: 100×, scale bar: 200 μm). After 48 h, invaded cells were counted by light microscopy. (D) The number of
invaded cells was normalized by dividing by the number of total cells to rule out the effect of cell proliferation and presented as the % of invasion. The results are shown as
the mean value ± SD (n = 3) and were analyzed by the Mann–Whitney U test (*p < 0.05). (E) The organotypic culture of IHOK/Control and IHOK/hTERT. Samples were stained
with cytokeratin to conﬁrm invaded cells (magniﬁcation: 100×, scale bar: 200 μm). (F) All invaded cells were counted and presented as the % of invasion. The results are
shown as the mean value ± SD (n = 3) and were analyzed by the Mann–Whitney U test (*p < 0.05).
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and EGR-1 in several OSCC cells. We selected OSCC cell line YD10B
because this cell line showed high levels of hTERT, FAP, and EGR-1
expression (Fig. S3A and B). hTERT depletion resulted in signiﬁ-
cantly reduced protein expression of FAP and EGR-1 compared with
control cells (Fig. S3C–E). In addition, we also veriﬁed that FAP was
regulated via EGR-1 in YD10B (Fig. S4C, D, G, and H), conﬁrming the
mechanism underlying hTERT-mediated regulation of FAP via EGR-1
in OSCC.
Invasion activity modulated by cathepsin D via EGR-1
To evaluate the importance of hTERT and EGR-1 in cell inva-
sion, we used siRNA to knock down the expression of hTERT and
EGR-1 in IHOK/hTERT and YD10B. The invasive activity was mark-
edly decreased both in hTERT-siRNA and EGR-1-siRNA transfected
cells compared with control cells, indicating that hTERT and EGR-1
regulated by hTERT play a critical role in upregulating cell inva-
sion in OSCC (Figs. 5A–C and 6A–C).
To better understand the molecular mechanism by which EGR-1
promotes invasive activity, the activities of MMP2 and MMP9 were
measured following EGR-1 depletion. No signiﬁcant change inMMP2
and MMP9 activities was observed between control cells and EGR-
1-siRNA transfected cells (Fig. 5D–F). Cathepsin D, another candidate
protease, was measured following EGR-1 depletion. The expression
of cathepsin D showed statistically signiﬁcant decrease in EGR-1-
siRNA transfected cells compared with control cells (Fig. 5G and H).
To searchwhether the regulation of cathepsin D expression by EGR-1
is related to ﬁbroblasts stimulation, we examined cathepsin D ex-
pression in EGR-1-siRNA transfected cells in co-cultured condition
with ﬁbroblasts. In the presence of ﬁbroblasts, no signiﬁcant dif-
ference in cathepsin D expression was observed between
monocultured (Fig. 5G and H) and co-cultured conditions (Fig. 5I and
J). To conﬁrm the effects of EGR-1 on the induction of cathepsin D
in OSCC cells, YD10B was transfected with EGR-1-siRNA. Cathep-
sin D expression was signiﬁcantly decreased following EGR-1
depletion (Fig. 6D–G), indicating that cathepsin D is regulated by
EGR-1 to modulate invasive activity. The presence of ﬁbroblasts did
not potentiate down-regulation of cathepsin D in YD10B.
Discussion
hTERT has been reported to have various functions in the in-
duction of cancer development and progression [7,8,25]. Despite
these observations, the precisemolecularmechanisms of these hTERT
functions have not been fully elucidated yet. In this study, we elu-
cidated, for the ﬁrst time, the mechanism underlying hTERT-
mediated regulation of the cysteine protease cathepsin D, which is
mediated by EGR-1.
To determine the molecular mechanism driving hTERT-mediated
tumor progression, we established an artiﬁcially manipulated OSCC
cell line (IHOK/hTERT) by overexpressing hTERT in IHOK. IHOK/
hTERT harbored higher in vivo tumorigenesis than IHOK/Control.
Accumulating evidence shows that hTERT is correlated with tumor
cell migration and invasion, independent of telomere-lengthening
function [7,26,27]. Thus, we assumed that the main driving force
leading to higher in vivo tumorigenesis in IHOK/hTERT may be at-
tributed to the high migratory or invasive potential, because no
difference in proliferating activity was found between IHOK/
Control and IHOK/hTERT. Providing evidence of a causal relationship
between proliferating activity and hTERT in vitro is diverse accord-
ing to cell types. Stable overexpression of hTERT in a hepatocellular
carcinoma did not affect cell proliferation [8]. In contrast, hTERT
transfection in osteosarcoma cells promoted cell proliferation [25].
The proliferation of hTERT-knockdown colorectal cancer cells was
inhibited after a prolonged period of time, suggesting that telomerase
activity remained after knockdown may be suﬃcient to maintain
telomere length and sustained growth [7]. Considering that BrdU
assay performed in our study did not reﬂect long-term proliferat-
ing effect of hTERT, we could focus on evaluating invasive activity
of hTERT.
To identify genes that could contribute to and promote cell in-
vasion by hTERT, microarray analysis was performed by comparing
gene expression between IHOK/Control and IHOK/hTERT. Among the
numerous invasion-related genes, cancer studies focused on the
gelatinases, MMPs, because they degrade type IV collagen, the main
component of the basement membrane. Speciﬁcally, MMP2 and
MMP9 are shown to play a crucial role in the invasion and metas-
tasis of OSCC. In our study, IHOK/hTERT showed higher expression
and activity of MMP2 and MMP9 compared with IHOK/Control,
which is consistent with our previous results [11].
Interestingly, the difference in invasive activity between two cell
lines in co-cultured conditions was enhanced compared withmono-
cultured condition (Fig. 3C and D). Cancer studies have acknowledged
that the stromal microenvironment plays a pivotal role in carcino-
genesis through crosstalk between cancer cells and stromal
ﬁbroblasts [28,29]. Previously, we reported a reciprocal interac-
tion between cancer cells and stromal ﬁbroblasts: IL1α, released from
the carcinoma, induced cytokine secretion in ﬁbroblasts, inducing
cancer cell invasion. Collectively, we hypothesized that hTERT may
Table 1
Invasion-related overexpressed genes in IHOK/hTERT compared with IHOK/Control.
Description Gene
symbol
IHOK/hTERT/IHOK/Control
intensity
Matrix metalloproteinase 9 MMP9 1.791236099
Nuclear factor of kappa light
polypeptide gene enhancer in B-cells
inhibitor, alpha
NFKBIA 1.435109233
TNF receptor-associated factor 4 TRAF4 1.407743952
Vascular endothelial growth factor A,
transcript variant 6
VEGFA 1.381553311
Matrix metalloproteinase 2 MMP2 1.366809303
TNF receptor-associated factor 4 TRAF4 1.237399983
Apoptotic peptidase activating factor 1,
transcript variant 3
APAF1 1.183889472
Vascular endothelial growth factor A,
transcript variant 1
VEGFA 1.168283047
v-akt murine thymoma viral oncogene
homolog 1, transcript variant 1
AKT1 1.147317564
Bone morphogenetic protein 2 BMP2 1.136742457
SATB homeobox 1, transcript variant 1 SATB1 1.130307847
Adrenergic, beta-2 ADRB2 1.104408898
Tumor necrosis factor TNF 1.10148696
Forkhead box K1 FOXK1 1.045099253
Vestigial like 4, transcript variant 2 VGLL4 1.038220356
Snail homolog 2 SNAI2 1.023804641
Nucleolin NCL 1.015369219
Golgi reassembly stacking protein 1 GORASP1 1.015262462
PIN2/TERF1 interacting, telomerase
inhibitor 1
PINX1 1.011766675
p53 and DNA-damage regulated 1 PDRG1 1.007545115
Cadherin 1 CDH1 1.000712434
Table 2
Fibroblast-related overexpressed genes in IHOK/hTERT compared with IHOK/Control.
Description Gene
symbol
IHOK/hTERT/IHOK/Control
intensity
1st 2nd 3rd
Fibroblast growth factor 2 FGF2 1.932276 2.00641 2.446
Fibroblast growth factor 11 FGF11 6.05235 3.24537 2.76532
Fibroblast growth factor
receptor 3
FGFR3 7.36015 4.76887 1.712476
Fibroblast activation protein FAP 3.35802 4.00645 4.68621
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stimulate the stromal microenvironments with tumor-associated
proteolytic enzymes and thus facilitate cancer cell invasion.
To conﬁrm our hypothesis, we collected microarray data to
compare gene expression between IHOK/Control and IHOK/hTERT.
Among the genes that were increased in IHOK/hTERT, we focused
on overexpressed ﬁbroblast-related genes, such as FGF2, FGF11,
FGFR3, and FAP (Table 2). Among these genes, FAP showed the great-
est difference between the two cell lines. FAP, a membrane gelatinase
of the serine protease family, is one of the controlling factors in ECM.
FAP itself induces degradation of localized ECM and cell invasion
in epithelial tumors [30–33]. It is commonly known that FAP is
mainly expressed in activated ﬁbroblasts during wound healing or
within tumor stromal ﬁbroblasts [34]. However, its expression has
also been shown in some types of malignant epithelial cells
[32,33,35]. It is also involved in the control of ﬁbroblast growth and
epithelial–mesenchymal interactions during carcinogenesis
[30–32,36–39]. In our study, we showed that FAP expression was
regulated by hTERT, as evidenced by reduced FAP expression fol-
lowing hTERT depletion.
To better understand the precise molecular mechanism of hTERT-
mediated invasive activity related to stromal interaction, mRNA
expressions of transcription factors that regulate FAP expressionwere
assessed. Among these transcription factors, only mRNA expres-
sion of EGR-1 was reduced by transfection with hTERT-siRNA in
IHOK/hTERT, indicating that hTERT could regulate FAP via EGR-1,
a regulatory factor of FAP. Consistent with these results, knock-
down of hTERT in YD10B OSCC cells reduced the expression of FAP
and EGR-1. The knockdown of hTERT also showed reduced inva-
siveness in IHOK/hTERT and YD10B. To evaluate the importance of
EGR-1 in the induction of invasiveness, an invasion assay was per-
formed after EGR-1 knockdown in IHOK/hTERT and YD10B. EGR-1
depletion resulted in a signiﬁcant reduction of invasion in both cell
lines, indicating that EGR-1 plays a crucial role in the induction of
invasiveness in OSCC. The present study shows that EGR-1 acts as
a positive regulator of tumor progression in OSCC. However, there
are contradictory ﬁndings of the roles of EGR-1, depending on the
cell type. EGR-1 has been considered to be a tumor suppressor in
breast, lung, and brain tumors, and a tumor promoter in kidney and
Fig. 4. FAP and EGR-1 regulation by hTERT. (A) mRNA expression for FAP, FGF2, FGF11, and FGFR3 in IHOK/Control and IHOK/hTERT. mRNA expressions for FAP, FGF2, FGF11,
and FGFR3 were measured by RT–PCR and GAPDH was used as a loading control. (B) Densitometric analysis of FAP, FGF2, FGF11, FGFR3 mRNA expression in IHOK/Control
and IHOK/hTERT. mRNA expression was normalized to each GAPDHmRNA expression. The results are shown as the mean value ± SD (n = 3) and were analyzed by the Mann–
Whitney U test (*p < 0.05). (C) mRNA expression of hTERT, FAP, and EGR-1 after transfection with hTERT-siRNA in IHOK/hTERT. GAPDH was used as a loading control. (D)
Protein expressions of FAP and EGR-1 after transfection with hTERT-siRNA in IHOK/hTERT. β-actin was used as a loading control. (E, F) Densitometric analysis of FAP and
EGR-1 protein expression after transfection with hTERT-siRNA in IHOK/hTERT. Protein expression was normalized to each β-actin expression. The results are shown as the
mean value ± SD (n = 3) and were analyzed by the Mann–Whitney U test (*p < 0.05).
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Fig. 5. Invasive activity modulated by cathepsin D via EGR-1 in IHOK/hTERT. (A) The invasion assay of IHOK/hTERT transfected with hTERT-siRNA and EGR-1-siRNA (mag-
niﬁcation: 100×, scale bar: 200 μm). After 48 h, invaded cells were counted by light microscopy. (B, C) The number of invaded cells was normalized by dividing by the number
of total cells to rule out the effect of cell proliferation and presented as the % of invasion. The results are shown as the mean value ± SD (n = 3) and were analyzed by the
Mann–Whitney U test (*p < 0.05). (D) MMP2 andMMP9 activities were examined by gelatin zymography in IHOK/Control, IHOK/hTERT, and EGR-1-siRNA transfected IHOK/hTERT.
HT1080 was used as a positive control. (E, F) Densitometric analysis of MMP2 and MMP9 activities in IHOK/Control, IHOK/hTERT, and EGR-1-siRNA transfected IHOK/hTERT.
The results are shown as the mean value ± SD (n = 3) and were analyzed by the Mann–Whitney U test (*p < 0.05). (G) Protein expression of EGR-1 and cathepsin D of EGR-
1-siRNA transfected IHOK/hTERT in the absence of ﬁbroblasts (w/o ﬁbroblasts). β-actin was used as a loading control. (H) Densitometric analysis of cathepsin D protein
expression in EGR-1-siRNA transfected IHOK/hTERT. Cathepsin D protein expression was normalized to each β-actin expression. The results are shown as the mean value ± SD
(n = 3) and were analyzed by the Mann–Whitney U test (*p < 0.05). (I) EGR-1 and cathepsin D protein expression of EGR-1-siRNA transfected IHOK/hTERT in the presence of
ﬁbroblasts (w/ﬁbroblasts). β-actin was used as a loading control. (J) Densitometric analysis of cathepsin D protein expression in EGR-1-siRNA transfected IHOK/hTERT co-
cultured with ﬁbroblasts. Cathepsin D protein expression was normalized to each β-actin expression. The results are shown as the mean value ± SD (n = 3) and were analyzed
by the Mann–Whitney U test (*p < 0.05).
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endothelial cell tumors [40–42]. One possible explanation for such
differences in the roles of EGR-1 is that its signal transduction
pathway is different in different cancer cells. We assessed whether
EGR-1 induces MMP2 and MMP9 expression based on previous
reports [43,44]. However, the activities of MMP2 and MMP9 were
not reduced after EGR-1 knockdown in IHOK/hTERT in our study.
Based on our previous study that cathepsin D expression was
increased by ﬁbroblast stimulation in collagen gel-based co-
culturedmodels [18], cathepsin D expression was assessed following
EGR-1 depletion. Cathepsin D expression was signiﬁcantly reduced
by transfection with EGR-1-siRNA in IHOK/hTERT and YD10B, in-
dicating that EGR-1 modulates the expression of cathepsin D to
induce invasive activity.
In our study, co-culture with ﬁbroblasts did not potentiate down-
regulation of cathepsin D in EGR-1-siRNA transfected cells, suggesting
that ﬁbroblasts cannot directly stimulate cancer cells to induce ca-
thepsin D expression. Further study will be required to elucidate
whether hTERT plays a direct role in cancer invasion by interac-
tion between cancer cells and ﬁbroblasts. According to a previous
study with breast cancer cells, ﬁbroblasts could not inﬂuence pro-
duction of cathepsin D [45]. The discrepancy from our previous
results that cathepsin D expression increased in OSCC cells by co-
culture with ﬁbroblasts could be attributed to the use of collagen-
gel based co-cultured models [18].
In summary, our study showed that hTERT induces cancer in-
vasion via MMP2, MMP9 as well as cathepsin D. We also
demonstrated that hTERT down-regulation could inhibit cancer in-
vasion through modulating cathepsin D expression via EGR-1. This
study could contribute to, and provide insight for, the develop-
ment of potential therapeutic targets for cancer treatment.
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